These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
506 related articles for article (PubMed ID: 17442267)
21. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. Sen S; Webber PJ; West AB J Biol Chem; 2009 Dec; 284(52):36346-36356. PubMed ID: 19826009 [TBL] [Abstract][Full Text] [Related]
22. LRRK2 autophosphorylation enhances its GTPase activity. Liu Z; Mobley JA; DeLucas LJ; Kahn RA; West AB FASEB J; 2016 Jan; 30(1):336-47. PubMed ID: 26396237 [TBL] [Abstract][Full Text] [Related]
23. Conformational heterogeneity of the Roc domains in C. tepidum Roc-COR and implications for human LRRK2 Parkinson mutations. Rudi K; Ho FY; Gilsbach BK; Pots H; Wittinghofer A; Kortholt A; Klare JP Biosci Rep; 2015 Aug; 35(5):. PubMed ID: 26310572 [TBL] [Abstract][Full Text] [Related]
24. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities. Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535 [TBL] [Abstract][Full Text] [Related]
25. Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations. Mills RD; Mulhern TD; Cheng HC; Culvenor JG Biochem Soc Trans; 2012 Oct; 40(5):1086-9. PubMed ID: 22988870 [TBL] [Abstract][Full Text] [Related]
26. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties. Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236 [TBL] [Abstract][Full Text] [Related]
27. Leucine-rich repeat kinase 2: relevance to Parkinson's disease. Guo L; Wang W; Chen SG Int J Biochem Cell Biol; 2006; 38(9):1469-75. PubMed ID: 16600664 [TBL] [Abstract][Full Text] [Related]
28. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity. Nguyen AP; Moore DJ Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279 [TBL] [Abstract][Full Text] [Related]
29. The small GTPase activity of the ROC domain from LRRK2, a Parkinson's disease related protein. Fu QS; Song AX; Li SX; Hu HY Protein Pept Lett; 2009; 16(12):1442-6. PubMed ID: 20001906 [TBL] [Abstract][Full Text] [Related]
30. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. Gandhi PN; Wang X; Zhu X; Chen SG; Wilson-Delfosse AL J Neurosci Res; 2008 Jun; 86(8):1711-20. PubMed ID: 18214993 [TBL] [Abstract][Full Text] [Related]
34. Parkinson-related LRRK2 mutation R1441C/G/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3. Muda K; Bertinetti D; Gesellchen F; Hermann JS; von Zweydorf F; Geerlof A; Jacob A; Ueffing M; Gloeckner CJ; Herberg FW Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E34-43. PubMed ID: 24351927 [TBL] [Abstract][Full Text] [Related]
35. Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics. Wu CX; Liao J; Park Y; Reed X; Engel VA; Hoang NC; Takagi Y; Johnson SM; Wang M; Federici M; Nichols RJ; Sanishvili R; Cookson MR; Hoang QQ J Biol Chem; 2019 Apr; 294(15):5907-5913. PubMed ID: 30796162 [TBL] [Abstract][Full Text] [Related]
37. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry. Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521 [TBL] [Abstract][Full Text] [Related]
38. A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover. Deyaert E; Wauters L; Guaitoli G; Konijnenberg A; Leemans M; Terheyden S; Petrovic A; Gallardo R; Nederveen-Schippers LM; Athanasopoulos PS; Pots H; Van Haastert PJM; Sobott F; Gloeckner CJ; Efremov R; Kortholt A; Versées W Nat Commun; 2017 Oct; 8(1):1008. PubMed ID: 29044096 [TBL] [Abstract][Full Text] [Related]
39. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. Greggio E; Lewis PA; van der Brug MP; Ahmad R; Kaganovich A; Ding J; Beilina A; Baker AK; Cookson MR J Neurochem; 2007 Jul; 102(1):93-102. PubMed ID: 17394548 [TBL] [Abstract][Full Text] [Related]
40. Autosomal dominant Parkinson's disease caused by the recently identified LRRK2 N1437D mutation in a Chinese family: Clinical features, imaging findings, and functional impact. Sun YM; Gan LH; Peng F; Zhou XY; Chen QS; Liu FT; Tang YL; Wu P; Lu JY; Ge JJ; Yen TC; Zuo CT; Song B; Wu JJ; Wang J Parkinsonism Relat Disord; 2023 Jun; 111():105441. PubMed ID: 37201327 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]